PharmExec Blog
Follow Us
RSS
Bookstore
Tag Archives: UK
Value-Based Pricing Could Counter Innovation, Says UK Think Tank
The UK government’s proposals to introduce value-based pricing (VBP) — which aims to create a stronger link between the price the National Health Service pays for a medicine and the value it delivers (and in the process, ostensibly, further incentivize therapeutic innovation) — could actually serve to ‘hinder’ innovation, according to a UK think tank.
Posted in Europe, Global, R&D, pricing Also tagged innovation, Pharma, PPRS, reimbursement, Stockholm Network, value-based pricing Leave a comment
Pfizer Site Closure "Shocking Wake-Up Call" for UK
It’s not too often that a pharma facility closure tops the TV news headlines but that was the case in the UK yesterday following Pfizer’s announcement that it is to close the UK-based R&D centre that achieved worldwide fame as “the home of Viagra”.
Posted in Europe, Strategy Also tagged closure, cost-cutting, Prizer, Sandwich, Viagra Leave a comment
NICE News or Bad News?
Far from losing its mojo, the UK’s National Institute for Health and Clinical Excellence (NICE) will simply be sharing the stage with a range of new players under NHS reform — none of whom look supportive of the R&D industry.
The big issue for industry in the UK this week is handicapping the future of its [...]
Posted in Europe, Global, Regulatory Also tagged Europe, health economics, legislation, NHS, NICE, pricing, Regulatory, value-based pricing Leave a comment
Cancer Testing Times: One Thing the UK Will Not Be Cutting
Buried among the savage, £83 billion-worth of cuts announced by the UK coalition government’s controversial Comprehensive Spending Review last week was confirmation that the Department of Health would not be taking forward the previous government’s pledge to introduce a one-week target for cancer testing.
Under the Labour government, the time that it took for a patient [...]
Posted in Europe, Global, Guest Blog Also tagged Cancer, diagnostics, health economics, Oncology Leave a comment
Patient Privacy Fears Taint UK Innovation Plans